Research Letter
Patients With Pouchitis Demonstrate a Significant Cost Burden in the First Two Years After Ileal Pouch-Anal Anastomosis

https://doi.org/10.1016/j.cgh.2021.09.037Get rights and content

Section snippets

Acknowledgments

The statements, findings, conclusions, and opinions contained and expressed in this manuscript are based in part on data obtained under license from the IQVIA Legacy PharMetrics Adjudicated Claims Data, All Rights Reserved. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IQVIA or any of its affiliated or subsidiary entities. Data were obtained under licensing from IQVIA, and thus requests for data sharing must comply with

First page preview

First page preview
Click to open first page preview

References (6)

  • J.O. Lindsay

    Aliment Pharmacol Ther

    (2015)
  • E.L. Barnes

    Clin Gastroenterol Hepatol

    (2021)
  • M.D. Long

    Inflamm Bowel Dis

    (2014)
There are more references available in the full text version of this article.

Cited by (3)

Conflicts of interest These authors disclose the following: Edward L. Barnes has served as a consultant for AbbVie, Gilead, Pfizer, Takeda, and Target RWE. Michael D. Kappelman has served as a consultant for AbbVie, Takeda, Janssen, and Eli Lilly; and has received research support from AbbVie and Janssen. Millie D. Long has served as a consultant for AbbVie, UCB, Takeda, Janssen, Pfizer, Salix, Valeant, and Target Pharmasolutions; and has received research support from Pfizer and Takeda. Hans H. Herfarth has served as a consultant for Alivio, AMAG, Finch, Gilead, Lycera, Merck, Otsuka, Pfizer, PureTech, and Seres; and has received research support from Pfizer and Artizan Biosciences. The remaining authors disclose no conflicts.

Funding This research was supported by grants from the Crohn’s & Colitis Foundation (567497 [ELB]) and the National Institutes of Health (K23DK127157-01 [ELB] and P30DK034987 [RSS]).

View full text